Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)

Neurobiology of Disease

Volumn 58, Issue , 2013, Pages 38-48

  Herzog, Christopher D ^a   Brown, Lamar ^a   Kruegel, Brian R ^a   Wilson, Alistair ^a   Tansey, Malú G ^b   Gage, Fred H ^c   Johnson, Eugene M ^d   Bartus, Raymond T ^a  

^a Ceregene Inc   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

6 hydroxydopamine; AAV NRTN; Animal model; Axon transport deficiencies; Axonopathy; Gene transfer; Neuronal survival; Neurotrophic factors; Neurturin; Parkinson's disease; Substantia nigra; Translational medicine

Indexed keywords

NEUROTROPHIC FACTOR; NEURTURIN; OXIDOPAMINE; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS SEROTYPE 2; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL FATE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG TARGETING; INTRACELLULAR SIGNALING; INTRANIGRAL DRUG ADMINISTRATION; INTRASTRIATAL DRUG ADMINISTRATION; MALE; NERVE FIBER DEGENERATION; NEURONAL TRANSPORT DEFICIT; NEUROPATHY; NEUROPROTECTION; NEUROTROPISM; NONHUMAN; PARKINSON DISEASE; PERIKARYON; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; VIRAL GENE DELIVERY SYSTEM;

6-HYDROXYDOPAMINE; AAV-NRTN; ANIMAL MODEL; AXON TRANSPORT DEFICIENCIES; AXONOPATHY; GENE TRANSFER; NEURONAL SURVIVAL; NEUROTROPHIC FACTORS; NEURTURIN; PARKINSON'S DISEASE; SUBSTANTIA NIGRA; TRANSLATIONAL MEDICINE;

ADENOVIRIDAE; ADRENERGIC AGENTS; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC VECTORS; MALE; MAP KINASE SIGNALING SYSTEM; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84879394186     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.04.011     Document Type: Article

References (51)

1. Bartus R.T. Translating the therapeutic potential of neurotrophic factors to clinical 'proof of concept': a personal saga achieving a career-long quest. Neurobiol. Dis. 2012, 48:153-178.
2. Bartus R.T., Herzog C.D., Chu Y., Wilson A., Brown L., Siffert J., Johnson E.M., Olanow C.W., Mufson E.J., Kordower J.H. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 2011, 26:27-36.
3. Bartus R.T., Brown L., Wilson A., Kruegel B., Siffert J., Johnson E.M., Kordower J.H., Herzog C.D. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol. Dis. 2011, 44:38-52.
4. Bartus R.T., Baumann T.L., Brown L., Kruegel B.R., Ostrove J.M., Herzog C.D. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiol. Aging 2013, 34:35-61.
5. Blandini F., Levandis G., Bazzini E., Nappi G., Armentero M.T. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur. J. Neurosci. 2007, 25:397-405.
6. Bowenkamp K.E., Hoffman A.F., Gerhardt G.A., Henry M.A., Biddle P.T., Hoffer B.J., Granholm A.C. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 1995, 355:479-489.
7. Burke R.E. Intracellular signalling pathways in dopamine cell death and axonal degeneration. Prog. Brain Res. 2010, 183:79-97.
8. Chen X., Liu W., Guoyuan Y., Liu Z., Smith S., Calne D.B., Chen S. Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson's disease. Parkinsonism Relat. Disord. 2003, 10:1-7.
9. Cheng H.C., Ulane C.M., Burke R.E. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 2010, 67:715-725.
10. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., Davidson B.L., Bohn M.C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997, 275:838-841.
11. Choi-Lundberg D.L., Lin Q., Schallert T., Crippens D., Davidson B.L., Chang Y.N., Chiang Y.L., Qian J., Bardwaj L., Bohn M.C. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol. 1998, 154:261-275.
12. Chu Y., Morfini G.A., Langhamer L.B., He Y., Brady S.T., Kordower J.H. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 2012, 135:2058-2073.
13. Chung C.Y., Koprich J.B., Siddiqi H., Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 2009, 29:3365-3373.
14. Ciesielska A., Mittermeyer G., Hadaczek P., Kells A.P., Forsayeth J., Bankiewicz K.S. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol. Ther. 2011, 19:922-927.
15. Connor B., Kozlowski D.A., Schallert T., Tillerson J.L., Davidson B.L., Bohn M.C. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 1999, 6:1936-1951.
16. Connor B., Kozlowski D.A., Unnerstall J.R., Elsworth J.D., Tillerson J.L., Schallert T., Bohn M.C. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. Exp. Neurol. 2001, 169:83-95.
17. De Vos K.J., Grierson A.J., Ackerley S., Miller C.C. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci. 2008, 31:151-173.
18. Decressac M., Mattsson B., Bjorklund A. Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Exp. Neurol. 2012, 235:306-315.
19. Decressac M., Kadkhodaei B., Mattsson B., Laguna A., Perlmann T., Bjorklund A. Alpha-synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci. Transl. Med. 2012, 10.1126/scitranslmed.3004676.
20. Gasmi M., Herzog C.D., Brandon E.P., Cunningham J.J., Ramirez G.A., Ketchum E.T., Bartus R.T. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol. Ther. 2007, 15:62-68.
21. Gasmi M., Brandon E.P., Herzog C.D., Wilson A., Bishop K.M., Hofer E.K., Cunningham J.J., Printz M.A., Kordower J.H., Bartus R.T. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol. Dis. 2007, 27:67-76.
22. Georgievska B., Kirik D., Bjorklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol. 2002, 177:461-474.
23. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
24. Grealish S., Xie L., Kelly M., Dowd E. Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat. Brain Res. Bull. 2008, 77:312-319.
25. Hilliard M.A. Axonal degeneration and regeneration: a mechanistic tug-of-war. J. Neurochem. 2009, 108:23-32.
26. Horger B.A., Nishimura M.C., Armanini M.P., Wang L.C., Poulsen K.T., Rosenblad C., Kirik D., Moffat B., Simmons L., Johnson E., Milbrandt J., Rosenthal A., Bjorklund A., Vandlen R.A., Hynes M.A., Phillips H.S. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 1998, 18:4929-4937.
27. Kells A.P., Forsayeth J., Bankiewicz K.S. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol. Dis. 2012, 48:228-235.
28. Kirik D., Rosenblad C., Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci. 2000, 12:3871-3882.
29. Kirik D., Rosenblad C., Bjorklund A., Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 2000, 20:4686-4700.
30. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., Bjorklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 2002, 22:2780-2791.
31. Kirik D., Georgievska B., Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci. 2004, 7:105-110.
32. Kozlowski D.A., Connor B., Tillerson J.L., Schallert T., Bohn M.C. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp. Neurol. 2000, 166:1-15.
33. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59:459-466.
34. Lee C.S., Sauer H., Bjorklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 1996, 72:641-653.
35. Mandel R.J., Rendahl K.G., Snyder R.O., Leff S.E. Progress in direct striatal delivery of l-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors. Exp. Neurol. 1999, 159:47-64.
36. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., Taylor R., Cahn-Weiner D.A., Stoessl A.J., Olanow C.W., Bartus R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008, 7:400-408.
37. Marks W.J., Bartus R.T., Siffert J., Davis C.S., Lozano A., Boulis N., Vitek J., Stacy M., Turner D., Verhagen L., Bakay R., Watts R., Guthrie B., Jankovic J., Simpson R., Tagliati M., Alterman R., Stern M., Baltuch G., Starr P.A., Larson P.S., Ostrem J.L., Nutt J., Kieburtz K., Kordower J.H., Olanow C.W. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010, 9:1164-1172.
38. McGrath J., Lintz E., Hoffer B.J., Gerhardt G.A., Quintero E.M., Granholm A.C. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion. Cell Transplant. 2002, 11:215-227.
39. Morfini G.A., Burns M., Binder L.I., Kanaan N.M., LaPointe N., Bosco D.A., Brown R.H., Brown H., Tiwari A., Hayward L., Edgar J., Nave K.A., Garberrn J., Atagi Y., Song Y., Pigino G., Brady S.T. Axonal transport defects in neurodegenerative diseases. J. Neurosci. 2009, 29:12776-12786.
40. O'Malley K.L. The role of axonopathy in Parkinson's disease. Exp. Neurobiol. 2010, 19:115-119.
41. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego, CA.
42. Raff M.C., Whitmore A.V., Finn J.T. Axonal self-destruction and neurodegeneration. Science 2002, 296:868-871.
43. Rosenblad C., Kirik D., Bjorklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol. 2000, 161:503-516.
44. Roy S., Zhang B., Lee V.M., Trojanowski J.Q. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol. 2005, 109:5-13.
45. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
46. Sauer H., Rosenblad C., Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:8935-8939.
47. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005, 102:216-222.
48. Smith A.D., Kozlowski D.A., Bohn M.C., Zigmond M.J. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats. Exp. Neurol. 2005, 193:420-426.
49. Walsh S., Finn D.P., Dowd E. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience 2011, 175:251-261.
50. West M.J., Slomianka L., Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 1991, 231:482-497.
51. Winkler C., Sauer H., Lee C.S., Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 1996, 16:7206-7215.